There were significant improvements in PFS for advanced NSCLC in the subgroups of sq-NSCLC, ECOG-2, and malignant pleural effusion (MPE) treated with ICIs plus endostatin (P = 0.02, P = 0.008, P = 0.037). The gene discussed is COL18A1; the disease is non-small cell lung carcinoma.